Cargando…
Development of vaccines for SARS-CoV-2
COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a fe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966/ https://www.ncbi.nlm.nih.gov/pubmed/32850116 http://dx.doi.org/10.12688/f1000research.25998.1 |
_version_ | 1783571691454070784 |
---|---|
author | Ng, Wern Hann Liu, Xiang Mahalingam, Suresh |
author_facet | Ng, Wern Hann Liu, Xiang Mahalingam, Suresh |
author_sort | Ng, Wern Hann |
collection | PubMed |
description | COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches. |
format | Online Article Text |
id | pubmed-7431966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-74319662020-08-25 Development of vaccines for SARS-CoV-2 Ng, Wern Hann Liu, Xiang Mahalingam, Suresh F1000Res Review COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches. F1000 Research Limited 2020-08-17 /pmc/articles/PMC7431966/ /pubmed/32850116 http://dx.doi.org/10.12688/f1000research.25998.1 Text en Copyright: © 2020 Ng WH et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Ng, Wern Hann Liu, Xiang Mahalingam, Suresh Development of vaccines for SARS-CoV-2 |
title | Development of vaccines for SARS-CoV-2 |
title_full | Development of vaccines for SARS-CoV-2 |
title_fullStr | Development of vaccines for SARS-CoV-2 |
title_full_unstemmed | Development of vaccines for SARS-CoV-2 |
title_short | Development of vaccines for SARS-CoV-2 |
title_sort | development of vaccines for sars-cov-2 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431966/ https://www.ncbi.nlm.nih.gov/pubmed/32850116 http://dx.doi.org/10.12688/f1000research.25998.1 |
work_keys_str_mv | AT ngwernhann developmentofvaccinesforsarscov2 AT liuxiang developmentofvaccinesforsarscov2 AT mahalingamsuresh developmentofvaccinesforsarscov2 |